Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Buqué, Aitziber, Bloy, Norma, Aranda, Fernando, Castoldi, Francesca, Eggermont, Alexander, Cremer, Isabelle, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Marabelle, Aurélien, Spisek, Radek, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2015
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485728/
https://ncbi.nlm.nih.gov/pubmed/26137403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1008814
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi